Literature DB >> 15340740

Management of acute coronary syndrome in diabetes mellitus.

Jim M John1, Deepak L Bhatt.   

Abstract

Diabetes mellitus is an increasingly prevalent condition in the modern era. Coronary artery disease is the major cause of mortality in this population. Despite advances in the therapeutic modalities available for management of coronary artery disease, diabetic patients tend to have worse short and long term outcomes. Acute coronary syndrome in this patient population should be managed aggressively with antithrombotic and antiplatelet agents, as well as early mechanical reperfusion strategies. Diabetic patients presenting with acute coronary syndrome benefit from intensive glycemic control in the first 48 hours. Percutaneous coronary angioplasty using drug-eluting stents with concomitant glycoprotein IIb/IIIa inhibitors should be considered early in diabetic patients with single vessel and multivessel disease. Long-term preventive measures include aspirin, clopidogrel, statins and angiotensin- converting enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340740     DOI: 10.1007/s00059-004-2614-0

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  3 in total

Review 1.  Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways.

Authors:  Mahmoud Fathi
Journal:  Glob Cardiol Sci Pract       Date:  2018-06-30

2.  Serum Calprotectin Levels and Outcome Following Percutaneous Coronary Intervention in Patients with Diabetes and Acute Coronary Syndrome.

Authors:  Chengji Wang; Yu Kong; Yuanyuan Ding; Jingzhi Sun; Tao Chen
Journal:  Med Sci Monit       Date:  2019-12-13

3.  Prognostic value of serum calprotectin level in elderly diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: A Cohort study.

Authors:  Wutang Zhang; Yongmei Kong; Lizhi Wang; Lizhong Song; Lijuan Tan; Xiaobo Xue
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.